Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Liposarcoma, drawn from the whole corpus: 8 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Retroperitoneal dedifferentiated disease recurs in most patients despite complete surgery.
MDM2 inhibitors cause low platelets that limit dosing.
No systemic therapy is proven in the adjuvant setting.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 10 changes by month →When this page itself was last checked or edited.
Abdominal recurrence-free survival not improved by preoperative radiotherapy; possible benefit in liposarcoma subgroups only.
A milestone in how this cancer is treated.
Pembrolizumab produced objective responses mainly in undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma, with little activity in bone sarcomas.
Unresectable or metastatic liposarcoma after anthracycline
A milestone in how this cancer is treated.